Kim Wopken1, Hendrik P Bijl2, Arjen van der Schaaf2, Hans Paul van der Laan2, Olga Chouvalova2, Roel J H M Steenbakkers2, Patricia Doornaert3, Ben J Slotman3, Sjoukje F Oosting4, Miranda E M C Christianen2, Bernard F A M van der Laan5, Jan L N Roodenburg6, C René Leemans7, Irma M Verdonck-de Leeuw7, Johannes A Langendijk2. 1. Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, The Netherlands. Electronic address: k.wopken@umcg.nl. 2. Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, The Netherlands. 3. Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands. 4. Department of Medical Oncology, University of Groningen, University Medical Center Groningen, The Netherlands. 5. Department of Otolaryngology/Head and Neck Surgery, University of Groningen, University Medical Center Groningen, The Netherlands. 6. Department of Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, The Netherlands. 7. Department of Otolaryngology-Head and Neck Surgery, VU University Medical Center, Amsterdam, The Netherlands.
Abstract
BACKGROUND AND PURPOSE: Curative radiotherapy/chemo-radiotherapy for head and neck cancer (HNC) may result in severe acute and late side effects, including tube feeding dependence. The purpose of this prospective cohort study was to develop a multivariable normal tissue complication probability (NTCP) model for tube feeding dependence 6 months (TUBEM6) after definitive radiotherapy, radiotherapy plus cetuximab or concurrent chemoradiation based on pre-treatment and treatment characteristics. MATERIALS AND METHODS: The study included 355 patients with HNC. TUBEM6 was scored prospectively in a standard follow-up program. To design the prediction model, the penalized learning method LASSO was used, with TUBEM6 as the endpoint. RESULTS: The prevalence of TUBEM6 was 10.7%. The multivariable model with the best performance consisted of the variables: advanced T-stage, moderate to severe weight loss at baseline, accelerated radiotherapy, chemoradiation, radiotherapy plus cetuximab, the mean dose to the superior and inferior pharyngeal constrictor muscle, to the contralateral parotid gland and to the cricopharyngeal muscle. CONCLUSIONS: We developed a multivariable NTCP model for TUBEM6 to identify patients at risk for tube feeding dependence. The dosimetric variables can be used to optimize radiotherapy treatment planning aiming at prevention of tube feeding dependence and to estimate the benefit of new radiation technologies.
BACKGROUND AND PURPOSE: Curative radiotherapy/chemo-radiotherapy for head and neck cancer (HNC) may result in severe acute and late side effects, including tube feeding dependence. The purpose of this prospective cohort study was to develop a multivariable normal tissue complication probability (NTCP) model for tube feeding dependence 6 months (TUBEM6) after definitive radiotherapy, radiotherapy plus cetuximab or concurrent chemoradiation based on pre-treatment and treatment characteristics. MATERIALS AND METHODS: The study included 355 patients with HNC. TUBEM6 was scored prospectively in a standard follow-up program. To design the prediction model, the penalized learning method LASSO was used, with TUBEM6 as the endpoint. RESULTS: The prevalence of TUBEM6 was 10.7%. The multivariable model with the best performance consisted of the variables: advanced T-stage, moderate to severe weight loss at baseline, accelerated radiotherapy, chemoradiation, radiotherapy plus cetuximab, the mean dose to the superior and inferior pharyngeal constrictor muscle, to the contralateral parotid gland and to the cricopharyngeal muscle. CONCLUSIONS: We developed a multivariable NTCP model for TUBEM6 to identify patients at risk for tube feeding dependence. The dosimetric variables can be used to optimize radiotherapy treatment planning aiming at prevention of tube feeding dependence and to estimate the benefit of new radiation technologies.
Authors: Primož Strojan; Katherine A Hutcheson; Avraham Eisbruch; Jonathan J Beitler; Johannes A Langendijk; Anne W M Lee; June Corry; William M Mendenhall; Robert Smee; Alessandra Rinaldo; Alfio Ferlito Journal: Cancer Treat Rev Date: 2017-07-18 Impact factor: 12.111
Authors: Michael Baumann; Mechthild Krause; Jens Overgaard; Jürgen Debus; Søren M Bentzen; Juliane Daartz; Christian Richter; Daniel Zips; Thomas Bortfeld Journal: Nat Rev Cancer Date: 2016-03-18 Impact factor: 60.716
Authors: Andrew Wentzel; Peter Hanula; Lisanne V van Dijk; Baher Elgohari; Abdallah S R Mohamed; Carlos E Cardenas; Clifton D Fuller; David M Vock; Guadalupe Canahuate; G E Marai Journal: Radiother Oncol Date: 2020-05-16 Impact factor: 6.280
Authors: Pierre Blanchard; Andrew J Wong; G Brandon Gunn; Adam S Garden; Abdallah S R Mohamed; David I Rosenthal; Joseph Crutison; Richard Wu; Xiaodong Zhang; X Ronald Zhu; Radhe Mohan; Mayankkumar V Amin; C David Fuller; Steven J Frank Journal: Radiother Oncol Date: 2016-09-15 Impact factor: 6.280
Authors: Diane Wenhua Chen; Jan S Lewin; Li Xu; Stephen Y Lai; G Brandon Gunn; Clifton David Fuller; Abdallah S R Mohamed; Aasheesh Kanwar; Erich M Sturgis; Katherine A Hutcheson Journal: Otolaryngol Head Neck Surg Date: 2016-10-03 Impact factor: 3.497
Authors: D Alterio; M A Gerardi; L Cella; R Spoto; V Zurlo; A Sabbatini; C Fodor; V D'Avino; M Conson; F Valoriani; D Ciardo; R Pacelli; A Ferrari; P Maisonneuve; L Preda; R Bruschini; M Cossu Rocca; E Rondi; S Colangione; G Palma; S Dicuonzo; R Orecchia; G Sanguineti; B A Jereczek-Fossa Journal: Strahlenther Onkol Date: 2017-09-07 Impact factor: 3.621